用于小鼠和大鼠神经干细胞和祖细胞分化培养的试剂盒

无血清,用于人神经干细胞和祖细胞的扩增培养

产品号 #(选择产品)

产品号 #05761_C

无血清,用于人神经干细胞和祖细胞的扩增培养

产品组分包括

  • NeuroCult™-XF基础培养基,450 mL
  • NeuroCult™-XF扩增添加物,50 mL

总览

NeuroCult™-XF 扩增培养基是一种标准化的无异种成分、无血清的培养基,适用于来源于正常组织或肿瘤样本的人神经干细胞/祖细胞在神经球或贴壁单层培养系统中进行体外培养。在添加适当的细胞因子后,该培养基经过优化,可长期维持人神经干细胞的体外培养状态,同时保持其自我更新、增殖及分化潜能。

注意:配制完全的培养体系时需添加无载体人重组 EGF(产品号 #78006)和人重组 bFGF(产品号 #78003)。可选添加肝素(产品号 #07980),但需注意肝素溶液含有非人源动物成分,如需构建完全无异种成分体系,则可省略肝素的添加。

亚型
专用培养基
 
细胞类型
脑肿瘤干细胞,神经干/祖细胞
 
种属

 
应用
细胞培养,克隆筛选,扩增,功能学筛选,球状体培养
 
品牌
NeuroCult
 
研究领域
癌症,疾病建模,药物发现和毒理检测,神经科学,干细胞生物学,移植研究
 
制剂类别
无血清,Xeno-Free
 

Data Figures

NSCs cultured in NeuroCult™-ACF Proliferation Medium maintain multi-lineage potential in long-term cultures

Figure 1. Neurospheres Derived from Human Fetal CNS Tissue can be Efficiently Generated for Multiple Passages in NeuroCult™-XF Proliferation Medium (n = 3)

Total cell expansion obtained with NeuroCult™-XF is comparable to that obtained with NeuroCult™ NS-A Proliferation Medium (Human).

Neurospheres derived from human fetal CNS tissue can be efficiently generated for multiple passages in NeuroCult™-ACF Proliferation Medium

Figure 2. NSCs Cultured in NeuroCult™-XF Proliferation Medium Maintain Multi-Lineage Differentiation Potential in Long-Term Cultures

The graph indicates the percentage of neurons (class III ß-tubulin-positive), astrocytes (GFAP-positive) and oligodendrocytes (O4-positive) generated following differentiation of NSCs previously cultured in NeuroCult™-XF or NeuroCult™ NS-A Proliferation Medium (Human). The differentiation potential of NSCs cultured in NeuroCult™-XF is comparable to NSCs cultured in NeuroCult™ NS-A Proliferation Medium (Human).

Protocols and Documentation

Find supporting information and directions for use in the Product Information Sheet or explore additional protocols below.

Document Type
Product Name
Catalog #
Lot #
Language
Catalog #
05761
Lot #
All
Language
English
Document Type
Technical Manual
Catalog #
05761
Lot #
All
Language
English
Document Type
Safety Data Sheet 1
Catalog #
05761
Lot #
All
Language
English
Document Type
Safety Data Sheet 2
Catalog #
05761
Lot #
All
Language
English

Applications

This product is designed for use in the following research area(s) as part of the highlighted workflow stage(s). Explore these workflows to learn more about the other products we offer to support each research area.

Resources and Publications

Educational Materials (11)

Publications (3)

The Use of Autologous Mesenchymal Stem Cells for Cell Therapy of Patients with Amyotrophic Lateral Sclerosis in Belarus. Rushkevich YN et al. Bulletin of experimental biology and medicine 2015 AUG

Abstract

We studied a new method of treatment of amyotrophic lateral sclerosis with autologous mesenchymal stem cells. Autologous mesenchymal stem cells were injected intravenously (intact cells) or via lumbar puncture (cells committed to neuronal differentiation). Evaluation of the results of cell therapy after 12-month follow-up revealed slowing down of the disease progression in 10 patients in comparison with the control group consisting of 15 patients. The cell therapy was safe for the patients.
Chemically defined serum-free and xeno-free media for multiple cell lineages. Usta S et al. Annals of translational medicine 2014 OCT

Abstract

Cell culture is one of the most common methods used to recapitulate a human disease environment in a laboratory setting. Cell culture techniques are used to grow and maintain cells of various types including those derived from primary tissues, such as stem cells and cancer tumors. However, a major confounding factor with cell culture is the use of serum and animal (xeno) products in the media. The addition of animal products introduces batch and lot variations that lead to experimental variability, confounds studies with therapeutic outcomes for cultured cells, and represents a major cost associated with cell culture. Here we report a commercially available serum-free, albumin-free, and xeno free (XF) media (Neuro-Pure(TM)) that is more cost-effective than other commercial medias. Neuro-Pure was used to maintain and differentiate various cells of neuronal lineages, fibroblasts, as well as specific cancer cell lines; without the use of contaminants such serum, albumin, and animal products. Neuro-Pure allows for a controlled and reproducible cell culture environment that is applicable to translational medicine and general tissue culture.
Hypoxia induces a phase transition within a kinase signaling network in cancer cells Wei W et al. Proceedings of the National Academy of Sciences 2013 APR

Abstract

Hypoxia is a near-universal feature of cancer, promoting glycolysis, cellular proliferation, and angiogenesis. The molecular mechanisms of hypoxic signaling have been intensively studied, but the impact of changes in oxygen partial pressure (pO2) on the state of signaling networks is less clear. In a glioblastoma multiforme (GBM) cancer cell model, we examined the response of signaling networks to targeted pathway inhibition between 21% and 1% pO2. We used a microchip technology that facilitates quantification of a panel of functional proteins from statistical numbers of single cells. We find that near 1.5% pO2, the signaling network associated with mammalian target of rapamycin (mTOR) complex 1 (mTORC1)--a critical component of hypoxic signaling and a compelling cancer drug target--is deregulated in a manner such that it will be unresponsive to mTOR kinase inhibitors near 1.5% pO2, but will respond at higher or lower pO2 values. These predictions were validated through experiments on bulk GBM cell line cultures and on neurosphere cultures of a human-origin GBM xenograft tumor. We attempt to understand this behavior through the use of a quantitative version of Le Chatelier's principle, as well as through a steady-state kinetic model of protein interactions, both of which indicate that hypoxia can influence mTORC1 signaling as a switch. The Le Chatelier approach also indicates that this switch may be thought of as a type of phase transition. Our analysis indicates that certain biologically complex cell behaviors may be understood using fundamental, thermodynamics-motivated principles.

更多信息

更多信息
Species Human
Formulation Category Serum-Free, Xeno-Free
Legal Statement: Sold under license from StemCells California, Inc. US Patent Nos. 5,750,376; 5,851,832; 5,980,885; 5,968,829; 5,981,165; 6,071,889; 6,093,531; 6,103,530; 6,165,783; 6,238,922. PRODUCTS ARE FOR RESEARCH USE ONLY AND NOT INTENDED FOR HUMAN OR ANIMAL DIAGNOSTIC OR THERAPEUTIC USES UNLESS OTHERWISE STATED. FOR ADDITIONAL INFORMATION ON QUALITY AT STEMCELL, REFER TO WWW.STEMCELL.COM/COMPLIANCE.
版权 © 2025 STEMCELL Technologies 技术有限公司。保留所有权利。